News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
505,497 Results
Type
Article (35136)
Company Profile (112)
Press Release (470249)
Multimedia
Podcasts (39)
Webinars (8)
Section
Business (139273)
Career Advice (794)
Deals (23016)
Drug Delivery (84)
Drug Development (60015)
Employer Resources (68)
FDA (14661)
Job Trends (10755)
News (242852)
Policy (24669)
Tag
Academia (2353)
Accelerated approval (4)
Adcomms (15)
Allergies (82)
Alliances (37851)
ALS (73)
Alzheimer's disease (1102)
Antibody-drug conjugate (ADC) (103)
Approvals (14705)
Artificial intelligence (222)
Autoimmune disease (19)
Automation (14)
Bankruptcy (180)
Best Places to Work (8779)
BIOSECURE Act (19)
Biosimilars (63)
Biotechnology (79)
Bladder cancer (65)
Brain cancer (24)
Breast cancer (234)
Cancer (1902)
Cardiovascular disease (144)
Career advice (683)
Career pathing (16)
CAR-T (119)
Cell therapy (314)
Cervical cancer (20)
Clinical research (49599)
Collaboration (659)
Compensation (210)
Complete response letters (15)
COVID-19 (2123)
CRISPR (34)
C-suite (178)
Cystic fibrosis (71)
Data (1860)
Decentralized trials (2)
Denatured (19)
Depression (35)
Diabetes (221)
Diagnostics (4927)
Digital health (14)
Diversity (5)
Diversity, equity & inclusion (18)
Drug discovery (83)
Drug pricing (75)
Drug shortages (26)
Duchenne muscular dystrophy (62)
Earnings (51063)
Editorial (29)
Employer branding (6)
Employer resources (63)
Events (70754)
Executive appointments (539)
FDA (15822)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (5)
Funding (545)
Gene editing (85)
Generative AI (16)
Gene therapy (217)
GLP-1 (529)
Government (3730)
Grass and pollen (3)
Guidances (54)
Healthcare (15362)
Huntington's disease (12)
IgA nephropathy (24)
Immunology and inflammation (84)
Indications (26)
Infectious disease (2222)
Inflammatory bowel disease (101)
Inflation Reduction Act (7)
Influenza (34)
Intellectual property (69)
Interviews (87)
IPO (9969)
IRA (26)
Job creations (2313)
Job search strategy (613)
Kidney cancer (9)
Labor market (11)
Layoffs (249)
Leadership (7)
Legal (4819)
Liver cancer (64)
Lung cancer (292)
Lymphoma (137)
Machine learning (5)
Management (25)
Manufacturing (216)
MASH (52)
Medical device (13899)
Medtech (13902)
Mergers & acquisitions (13451)
Metabolic disorders (539)
Multiple sclerosis (73)
NASH (13)
Neurodegenerative disease (73)
Neuropsychiatric disorders (17)
Neuroscience (1533)
NextGen: Class of 2025 (5082)
Non-profit (3414)
Now hiring (20)
Obesity (269)
Opinion (134)
Ovarian cancer (62)
Pain (82)
Pancreatic cancer (68)
Parkinson's disease (110)
Partnered (15)
Patents (164)
Patient recruitment (96)
Peanut (45)
People (42293)
Pharmaceutical (31)
Pharmacy benefit managers (16)
Phase I (15130)
Phase II (21618)
Phase III (16933)
Pipeline (915)
Policy (104)
Postmarket research (1894)
Preclinical (5711)
Press Release (59)
Prostate cancer (93)
Psychedelics (20)
Radiopharmaceuticals (182)
Rare diseases (274)
Real estate (4122)
Recruiting (27)
Regulatory (17899)
Reports (21)
Research institute (2090)
Resumes & cover letters (124)
Rett syndrome (4)
RNA editing (2)
RSV (27)
Schizophrenia (61)
Series A (97)
Series B (65)
Service/supplier (7)
Sickle cell disease (35)
Special edition (6)
Spinal muscular atrophy (122)
Sponsored (24)
Startups (2738)
State (1)
Stomach cancer (14)
Supply chain (55)
Tariffs (26)
The Weekly (20)
Vaccines (514)
Venture capitalists (24)
Weight loss (174)
Women's health (21)
Worklife (6)
Date
Today (81)
Last 7 days (622)
Last 30 days (1913)
Last 365 days (24352)
2025 (7953)
2024 (26278)
2023 (30144)
2022 (40322)
2021 (43202)
2020 (42202)
2019 (36535)
2018 (27925)
2017 (24799)
2016 (23907)
2015 (28046)
2014 (21158)
2013 (17712)
2012 (19176)
2011 (19821)
2010 (17811)
Location
Africa (506)
Alabama (29)
Alaska (4)
Arizona (182)
Arkansas (12)
Asia (35789)
Australia (4901)
California (4151)
Canada (1469)
China (546)
Colorado (193)
Connecticut (211)
Delaware (137)
Europe (65431)
Florida (716)
Georgia (161)
Idaho (44)
Illinois (419)
India (22)
Indiana (282)
Iowa (5)
Japan (139)
Kansas (84)
Kentucky (18)
Louisiana (10)
Maine (35)
Maryland (744)
Massachusetts (3070)
Michigan (163)
Minnesota (302)
Mississippi (2)
Missouri (75)
Montana (26)
Nebraska (21)
Nevada (42)
New Hampshire (65)
New Jersey (1374)
New Mexico (20)
New York (1282)
North Carolina (718)
North Dakota (6)
Northern California (1801)
Ohio (167)
Oklahoma (6)
Oregon (30)
Pennsylvania (1035)
Puerto Rico (11)
Rhode Island (29)
South America (731)
South Carolina (23)
South Dakota (1)
Southern California (1584)
Tennessee (84)
Texas (699)
United States (16887)
Utah (152)
Virginia (114)
Washington D.C. (47)
Washington State (372)
West Virginia (3)
Wisconsin (48)
505,497 Results for "china medical systems".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Tariffs
China Still Go-To Source for New Drugs Despite Tariff Minefield
Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a tightrope on their relations with China.
April 30, 2025
·
10 min read
·
Annalee Armstrong
Policy
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
China Medical System Holdings Limited is pleased to announce that on 11 June 2024, the New Drug Application of the Group’s innovative drug methylthioninium chloride enteric-coated sustained-release tablets has been approved by the National Medical Products Administration of China.
June 18, 2024
·
7 min read
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets (“Desidustat Tablets” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA).
April 23, 2024
·
4 min read
Press Releases
Baird Medical Presents Advanced MWA Technology to UCLA Expert in China
April 14, 2025
·
5 min read
Drug Development
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the “Product”) in atopic dermatitis (“AD”) in China.
June 25, 2024
·
8 min read
Press Releases
Baird Medical Hosts Malaysian Thyroid Specialists for Advanced Microwave Ablation Training in China
April 24, 2025
·
5 min read
China
AstraZeneca Makes Potential $10B+ China Commitment Despite Political Pressure
The investments come amid an ongoing insurance fraud probe into AstraZeneca’s former China head Leon Wang—and despite mounting pressure from President Trump for pharma companies to re-shore their manufacturing operations.
March 24, 2025
·
2 min read
·
Tristan Manalac
Press Releases
MediBeacon® Transdermal GFR System receives device approval in China
February 26, 2025
·
8 min read
Press Releases
Promega ProDx MSI Detection Kit Receives NMPA Innovative Medical Device Registration Certificate in China
April 29, 2025
·
2 min read
Mergers & acquisitions
AstraZeneca Buys FibroGen’s China Unit for $160M as Probes Continue
A year ago, AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.
February 20, 2025
·
2 min read
·
Tristan Manalac
1 of 50,550
Next
